{"id":"efficacy-of-ceftaroline","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Phlebitis at infusion site"},{"rate":null,"effect":"Hypersensitivity reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ceftaroline fosamil is a prodrug that is converted to ceftaroline, which has enhanced activity against gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA) compared to earlier-generation cephalosporins. It binds to bacterial penicillin-binding proteins and inhibits cross-linking of peptidoglycan, leading to cell wall disruption and bacterial death. The drug has broad-spectrum activity against both gram-positive and gram-negative organisms.","oneSentence":"Ceftaroline is a fifth-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:46:13.999Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Community-acquired bacterial pneumonia (CABP)"},{"name":"Acute bacterial skin and skin structure infections (ABSSSI)"},{"name":"Methicillin-resistant Staphylococcus aureus (MRSA) infections"}]},"trialDetails":[{"nctId":"NCT01734694","phase":"PHASE4","title":"Safety and Efficacy of Strategy to Prevent Drug-Induced Nephrotoxicity in High-Risk Patients","status":"TERMINATED","sponsor":"Henry Ford Health System","startDate":"2011-10","conditions":"Health Care Associated Pneumonia, Osteomyelitis/Septic Arthritis, Endocarditis","enrollment":100},{"nctId":"NCT01756924","phase":"PHASE2","title":"Safety and Efficacy of CEM-102 With Rifampin Compared to Standard Therapy in Patients With Prosthetic Joint Infections or Spacer Infection","status":"TERMINATED","sponsor":"Arrevus Inc.","startDate":"2012-12","conditions":"Prosthetic Joint Infections of Hip, Prosthetic Joint Infections of Knee, Infected Spacers","enrollment":14},{"nctId":"NCT02424734","phase":"PHASE2","title":"Safety, Tolerability and Efficacy of Ceftaroline in Paediatrics With Late-Onset Sepsis","status":"TERMINATED","sponsor":"Pfizer","startDate":"2015-08-04","conditions":"Late-onset Sepsis","enrollment":11},{"nctId":"NCT01371838","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Intravenous Ceftaroline Versus Intravenous Ceftriaxone in the Treatment of Adult Hospitalised Patients With Community-Acquired Bacterial Pneumonia in Asia","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-12","conditions":"Community-Acquired Bacterial Pneumonia, Lung Infection of Individual Not Recently Hospitalized","enrollment":848},{"nctId":"NCT02202135","phase":"PHASE3","title":"Evaluation of Ceftaroline Fosamil vs Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections.","status":"TERMINATED","sponsor":"Pfizer","startDate":"2014-06","conditions":"Complicated Skin and Soft Tissue Infection","enrollment":4},{"nctId":"NCT01499277","phase":"PHASE3","title":"Evaluation of Ceftaroline Fosamil Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-05","conditions":"Complicated Skin and Soft Tissue Infection","enrollment":802},{"nctId":"NCT00424190","phase":"PHASE3","title":"Comparative Study of Ceftaroline vs. Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin Infections","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2007-02","conditions":"Bacterial Infections","enrollment":698},{"nctId":"NCT00633152","phase":"PHASE2","title":"Efficacy and Safety of Ceftaroline Versus Linezolid in Subjects With Complicated Skin and Skin Structure Infections","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2008-02","conditions":"Bacterial Infection","enrollment":150},{"nctId":"NCT00509106","phase":"PHASE3","title":"Comparative Study of Ceftaroline vs. Ceftriaxone in Adults With Community-Acquired Pneumonia","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2007-07","conditions":"Bacterial Pneumonia","enrollment":622},{"nctId":"NCT00621504","phase":"PHASE3","title":"Comparative Study of Ceftaroline vs. Ceftriaxone in Adult Subjects With Community-Acquired Pneumonia","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2008-01","conditions":"Bacterial Pneumonia","enrollment":606},{"nctId":"NCT00423657","phase":"PHASE3","title":"Comparative Study of Ceftaroline vs. Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin Infections","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2007-03","conditions":"Bacterial Infections","enrollment":680},{"nctId":"NCT01645735","phase":"PHASE4","title":"Evaluation of Ceftaroline Fosamil Versus a Comparator in Adult Subjects With Community-acquired Bacterial Pneumonia (CABP) With Risk for Methicillin-resistant Staphylococcus Aureus","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2012-10","conditions":"Infections","enrollment":49},{"nctId":"NCT01669980","phase":"PHASE4","title":"Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Complicated Community Acquired Pneumonia (CABP)","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2012-10","conditions":"Infections, Pneumonia","enrollment":40},{"nctId":"NCT01400867","phase":"PHASE2, PHASE3","title":"Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Complicated Skin Infections","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2011-12","conditions":"Infections, Pediatrics","enrollment":163},{"nctId":"NCT01530763","phase":"PHASE2, PHASE3","title":"Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Community Acquired Bacterial Pneumonia (CABP)","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2012-09","conditions":"Infections, Community Acquired Pneumonia","enrollment":161},{"nctId":"NCT01701219","phase":"PHASE4","title":"Safety and Efficacy Study of Ceftaroline in Subjects With Staphylococcus Aureus Bacteremia or With Persistent Methicillin-Resistant Staphylococcus Aureus Bacteremia","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2013-01","conditions":"Staphylococcus Aureus Bacteremia, Methicillin-resistant Staphylococcus Aureus (MRSA) Bacteremia","enrollment":56},{"nctId":"NCT01605864","phase":"PHASE3","title":"Use of Ceftaroline in Hospitalized Patients With Community Acquired Pneumonia","status":"COMPLETED","sponsor":"Albany Medical College","startDate":"2012-05","conditions":"Community Acquired Bacterial Pneumonia","enrollment":12},{"nctId":"NCT01281462","phase":"PHASE2","title":"Comparative Study of Coadministered Ceftaroline Fosamil and NXL104 vs. Intravenous Doripenem in Adult Subjects With Complicated Urinary Tract Infections","status":"COMPLETED","sponsor":"Forest Laboratories","startDate":"2010-12","conditions":"Urinary Tract Infections","enrollment":217},{"nctId":"NCT01666743","phase":"PHASE4","title":"Safety and Efficacy Study of Ceftaroline in Elderly Subjects With Community-Acquired Bacterial Pneumonia","status":"WITHDRAWN","sponsor":"Forest Laboratories","startDate":"2012-11","conditions":"Community-Acquired Bacterial Pneumonia (CABP)","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":228,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Efficacy of ceftaroline","genericName":"Efficacy of ceftaroline","companyName":"Albany Medical College","companyId":"albany-medical-college","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ceftaroline is a fifth-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. Used for Community-acquired bacterial pneumonia (CABP), Acute bacterial skin and skin structure infections (ABSSSI), Methicillin-resistant Staphylococcus aureus (MRSA) infections.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}